Korean Bio Stocks Fall Across the Board on Weak U.S. Market... Declines Deepen for HLB, Alteogen, and Hanall Biopharma
Domestic bio stocks were trading broadly lower in the morning session on the 10th. Major names including HLB, Alteogen, Hanall Biopharma, OliX Pharmaceuticals, and ABL Bio are seeing their losses widen. The weakness follows an overnight decline on the U.S. stock market, with somewhat subdued invest

Domestic bio stocks were trading broadly lower in the morning session on the 10th. Major names including HLB, Alteogen, Hanall Biopharma, OliX Pharmaceuticals, and ABL Bio are seeing their losses widen.
The weakness follows an overnight decline on the U.S. stock market, with somewhat subdued investor sentiment toward local bio and healthcare stocks weighing on the Korean market.
HLB Falls 2.86%... Most Affiliates Also Weak
HLB was trading down 2.86% at 30,600 won, 900 won lower than the previous session. The stock opened at 31,650 won and rose as high as 31,750 won before slipping to 30,550 won and turning lower.
Most HLB affiliates were also weak. HLB Pharmaceutical was down a notable 4.08% at 6,590 won. HLB Life Science fell 1.81% to 2,435 won, and HLB Therapeutics was trading 1.15% lower at 1,976 won. HLB Genex, HLB Global, and HLB Biostep declined 1.10%, 0.97%, and 0.87%, respectively.
Some affiliates, however, moved differently. HLB Innovation rose 0.47% to 15,100 won, and HLB PEP gained 1.68% to 4,235 won.
Alteogen Falls 3.85%... Correction Continues for Large-Cap Bio Stocks
The correction in large-cap bio stocks continued. Alteogen dropped 3.85% to 268,750 won, down 10,750 won, while Samsung Biologics traded 2.20% lower at 1.42 million won. Celltrion also fell 1.53% to 180,300 won.
Hanall Biopharma Plunges 7.00%... Mid-Cap Stocks See Steeper Losses
One of the steepest decliners was Hanall Biopharma, which fell 7.00% to 50,500 won, down 3,800 won from the previous session. OliX Pharmaceuticals dropped 5.75% to 93,500 won, Curient fell 4.89% to 21,400 won, and ABL Bio declined 4.64% to 65,800 won.
During the session, HLB and its affiliates, along with Alteogen, Hanall Biopharma, OliX Pharmaceuticals, and ABL Bio, all slid simultaneously, making the sector-wide weakness relatively pronounced. However, as each company's pipeline and clinical trial progress differ, it is advisable to consider individual catalysts rather than interpreting the movement of domestic bio stocks solely based on the weak U.S. market.
[This article is for reference only in making investment decisions and does not recommend buying or selling any specific stock. The final decision and responsibility for investments rest with the investor. AI was used in compiling the information.]
CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.


![[Breaking] Evernos Holdings (XRPN) Flat at $7.45... Bitcoin at $64,922, Market on Alert Over Weakness in Leading Stock](/_next/image?url=https%3A%2F%2Fmedia.cbcglobe.com%2Ftenants%2Fcbc00000-0000-4000-8000-000000000001%2Fmedia%2Fcbc%2F2026%2F11%2F626848%2F4c15339f3668573e%2Fvariants%2Fhero.webp&w=1920&q=75)
